NewsSTAT
Heuristic editor, no API keyVerdict: RoutineSTAT+: Why a Huntington's patient isn't fazed by the waning effect of UniQure's gene therapy
Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street.
Score█████░░░░░4.8
VerdictCompetent work. Briefs at most.
Summary from the source
Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 15% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 10% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ██░░░ 2 | 25% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars); stakes (prevention or cure).
How the score was computed
Score█████░░░░░4.8
- Merit
- 4.4 / 10
- Adjusted merit
- 4.1 / 10
- Attention
- 28%
- Freshness
- 81%